e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Pulmonary venous thromboembolic disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
5 year survival of patients with distal chronic thromoembolic pulmonary hypertension; comparison of treated patients with distal disease and residual disease post pulmonary endartectomy
C. Treacy, K. Page, R. Mackenzie Ross, G. Hagan, J. Pepke-Zaba, D. Jenkins (Cambridge, United Kingdom)
Source:
Annual Congress 2010 - Pulmonary venous thromboembolic disease
Session:
Pulmonary venous thromboembolic disease
Session type:
E-Communication Session
Number:
3888
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Treacy, K. Page, R. Mackenzie Ross, G. Hagan, J. Pepke-Zaba, D. Jenkins (Cambridge, United Kingdom). 5 year survival of patients with distal chronic thromoembolic pulmonary hypertension; comparison of treated patients with distal disease and residual disease post pulmonary endartectomy. Eur Respir J 2010; 36: Suppl. 54, 3888
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy?
Source: Annual Congress 2005 - News about pulmonary embolism
Year: 2005
A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development
Source: Eur Respir J 2003; 22: Suppl. 45, 221s
Year: 2003
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020
Year: 2020
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
The association of diuretics treatment with hospitalization rates of patients with chronic obstructive pulmonary disease and pulmonary hypertension: a population-based study
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
How to detect disease progression in pulmonary arterial hypertension
Source: Eur Respir Rev 2012; 21: 40-47
Year: 2012
Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)?
Source: Eur Respir J 2001; 18: Suppl. 33, 241s
Year: 2001
Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
Does pulmonary rehabilitation improve mortality in patients with chronic obstructive pulmonary disease (COPD)?
Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD
Year: 2017
The impact of immediate postoperative pulmonary vascular resistance on survival in patients with chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary embolism
Year: 2009
Does lung volume reduction surgery improve chronotropic incompetence in chronic obstructive pulmonary disease (COPD) patients?
Source: Annual Congress 2011 - Pleural diseases and pneumothorax
Year: 2011
Pulmonary function in patients with chronic obstructive pulmonary disease (COPD) at the remote period after radiation exposure
Source: Eur Respir J 2007; 30: Suppl. 51, 338s
Year: 2007
An early prediction of intravascular microthromb formation for patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005
Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era
Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension
Year: 2018
The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD)
Source: Eur Respir J 2007; 30: Suppl. 51, 345s
Year: 2007
Accuracy of pre-operative specimen level prediction in chronic thromboembolic pulmonary hypertension (CTEPH) patients undergoing pulmonary thromboendarterectomy (PTE)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept